HC Wainwright Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 441.52% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Benchmark reissued a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Trading Down 7.4 %

Shares of NASDAQ HUMA opened at $2.77 on Wednesday. The stock has a market capitalization of $348.63 million, a price-to-earnings ratio of -2.07 and a beta of 1.36. Humacyte has a 12-month low of $2.75 and a 12-month high of $9.97. The firm’s 50-day moving average price is $4.00 and its 200-day moving average price is $4.75.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp lifted its position in shares of Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after buying an additional 1,895,529 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Humacyte during the 3rd quarter worth $596,000. Thrivent Financial for Lutherans purchased a new stake in Humacyte in the third quarter valued at $712,000. Barclays PLC boosted its stake in Humacyte by 177.6% in the third quarter. Barclays PLC now owns 236,742 shares of the company’s stock valued at $1,288,000 after acquiring an additional 151,458 shares in the last quarter. Finally, Brookstone Capital Management acquired a new position in Humacyte in the fourth quarter valued at $56,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.